Browse categories and answer follow-up questions to refine your symptom profile.
Approach to the Critical Patient
Immediate risk stratification
High-risk presentation screen
Hemodynamic instability
SBP < 90 mmHg
Altered mental status
Airway threat
Stridor
Inability to handle secretions
Significant gastrointestinal bleeding
Hematemesis
Melena with syncope
Esophageal perforation concern
Severe chest pain after vomiting
Subcutaneous emphysema
Acute coronary syndrome not yet excluded
Chest pressure with exertion
Diaphoresis
Immediate actions if unstable
If shock, resuscitation bay and parallel workup
IV access and monitoring
ECG within 10 minutes for chest pain equivalent
If active hematemesis, massive GI bleed pathway
Blood product preparation
Early gastroenterology consultation
If perforation concern, broad-spectrum antibiotics and urgent CT chest with water-soluble contrast pathway
Surgical consultation
NPO status
Chest pain safety overlay
Noncardiac chest pain diagnosis only after appropriate cardiac evaluation
Serial high-sensitivity troponin per local protocol
Risk stratification tool per ED chest pain guideline
ACEP chest pain guidance alignment
Level A or Level B local pathway adherence for ECG and troponin in suspected ACS
Avoid anchoring on reflux with ongoing ischemic concern
Key concepts
Working diagnosis framework
GERD symptom syndromes
Typical reflux syndrome
Heartburn
Regurgitation
Extraesophageal reflux syndrome
Chronic cough
Laryngitis symptoms
Complication syndromes
Erosive esophagitis
Odynophagia
GI bleeding signs
Stricture
Progressive solid food dysphagia
Barrett esophagus risk phenotype
Long-standing frequent symptoms
Multiple risk factors
Diagnostic strategy principle
Empiric PPI trial appropriate for typical symptoms without alarm features
Symptom response supports GERD but does not fully exclude alternative diagnoses
Alarm features trigger early endoscopy rather than prolonged empiric therapy
Dysphagia
Unintentional weight loss
GI bleeding or anemia
History
Symptom characterization
Reflux symptom profile
Heartburn
Substernal burning
Postprandial pattern
Regurgitation
Sour or bitter fluid sensation
Worse when bending or supine
Chest pain
Relationship to meals
Exertional component
Dyspepsia overlap
Epigastric discomfort
Early satiety
Temporal pattern
Duration
Onset date
Symptom frequency per week
Diurnal variation
Nocturnal symptoms
Morning hoarseness
Prior episodes
Previous response to acid suppression
Prior endoscopy results
Alarm features and complication clues
Alarm features
Dysphagia
Solids then liquids progression
Food impaction events
Odynophagia
Severe pain with swallowing
Immunosuppression context
GI bleeding
Hematemesis
Melena
Unintentional weight loss
Documented decline
Reduced intake due to symptoms
Persistent vomiting
Dehydration signs
Electrolyte concern
Complication clues
Stricture symptoms
Progressive dysphagia
Need for liquids to pass food
Aspiration risk
Choking episodes at night
Recurrent pneumonias
Barrett risk profile
Long-standing symptoms
Family history of Barrett or esophageal adenocarcinoma
Triggers, exposures, and risk factors
Dietary triggers
Large meals
Postprandial worsening
Late-night eating
Common trigger foods
High-fat meals
Chocolate
Caffeine and carbonated beverages
Symptom correlation
Quantity per day
Lifestyle factors
Tobacco use
Current use
Pack-year estimate
Alcohol use
Pattern and quantity
Symptom association
Obesity
Recent weight gain
Central adiposity
Medication contributors
Reduced LES tone potential
Calcium channel blockers
Nitrates
Pill esophagitis risk
Doxycycline
Bisphosphonates
Mucosal injury risk
NSAIDs
Aspirin
Physical Exam
General and vital signs
Physiologic status
Vitals
Tachycardia
Fever
Hydration
Dry mucous membranes
Orthostasis
General appearance
Toxic appearance
Sepsis concern
Perforation concern
Pain behavior
Severe distress
Unable to tolerate oral intake
Focused examination
Oropharynx and neck
Oropharyngeal findings
Erythema
Thrush
Neck exam
Tenderness
Crepitus
Cardiopulmonary
Cardiac exam
New murmur
Rhythm irregularity
Lung exam
Wheeze
Rales suggesting aspiration
Abdomen
Epigastric tenderness
Mild localized tenderness
Guarding suggests alternative diagnosis
Peritoneal signs
Rebound tenderness
Rigidity
Signs of bleeding or anemia
Conjunctival pallor
Symptomatic anemia concern
Need for CBC
Rectal exam when indicated
Melena
Hematochezia
Differential Diagnosis
Life-threatening and must-not-miss
Cardiac
Acute coronary syndrome
ICD-10 I20.0
SNOMED CT acute coronary syndrome
Aortic dissection
ICD-10 I71.0
Severe tearing pain phenotype
Pericarditis
ICD-10 I30.9
Pleuritic pain and positional relief
Pulmonary
Pulmonary embolism
ICD-10 I26.99
Pleuritic pain and dyspnea
Pneumothorax
ICD-10 J93.9
Unilateral decreased breath sounds
Gastrointestinal emergencies
Esophageal perforation
ICD-10 K22.3
Severe pain after vomiting
Upper GI bleed
ICD-10 K92.2
Hematemesis or melena
Common mimics and overlaps
Esophageal disorders
Eosinophilic esophagitis
Food impaction history
Atopy history
Achalasia
Progressive dysphagia
Regurgitation of undigested food
Esophageal spasm
Intermittent chest pain
Dysphagia episodes
Gastric and duodenal disorders
Functional dyspepsia
Postprandial fullness
Epigastric pain syndrome
Peptic ulcer disease
NSAID exposure
Nocturnal pain pattern
Hepatobiliary and pancreatic
Biliary colic
RUQ pain after fatty meals
Radiation to back or shoulder
Acute cholecystitis
Fever and RUQ tenderness
Positive Murphy sign
Pancreatitis
Epigastric pain to back
Lipase elevation
Laboratory Tests
Basic tests when indicated
Targeted labs by phenotype
Complete blood count for bleeding or anemia concern
Low hemoglobin suggests GI blood loss
Leukocytosis suggests infection or complication
Electrolytes and renal function for vomiting or dehydration
Hypokalemia with prolonged emesis
AKI risk with poor intake
Liver enzymes and bilirubin for RUQ pain or biliary concern
Cholestatic pattern suggests biliary obstruction
Marked transaminitis suggests alternative diagnosis
Lipase for pancreatitis phenotype
Elevation supports pancreatitis
Normal value does not exclude early disease
Pregnancy testing
Beta hCG for reproductive potential
Hyperemesis differential
Medication selection implications
Cardiac and pulmonary rule-out labs
Chest pain safety labs
High-sensitivity troponin when ACS in differential
Serial testing per protocol
Normal early value may require repeat testing
D-dimer when PE workup appropriate
Use only with low or intermediate pretest probability
Avoid in high pretest probability as rule-out strategy
H pylori and anemia evaluation
H pylori testing context
Dyspepsia predominant phenotype
Stool antigen testing option
Urea breath testing option
Testing caveats with acid suppression
PPI can reduce test sensitivity
Recent antibiotics can reduce test sensitivity
Iron studies when chronic blood loss suspected
Ferritin
Low ferritin supports iron deficiency
Inflammation can elevate ferritin
Transferrin saturation
Low saturation supports iron deficiency
Consider chronic disease anemia alternative
Diagnostic Tests
Scoring Systems
Symptom-based tools
GERD-Q questionnaire
Higher scores increase probability of GERD
Best use in primary care phenotype
Alarm feature checklist
Any alarm feature prompts early endoscopy pathway
Persistent dysphagia prompts urgent evaluation
ED risk tools for chest pain overlap
HEART score for chest pain phenotype
Supports ACS risk stratification
Not a GERD diagnostic tool
ACEP aligned chest pain pathways
Level A or Level B recommendation adherence per institution
Shared decision-making documentation for low-risk discharge
MRI
Limited role in uncomplicated GERD
Routine MRI not indicated for typical symptoms
Low diagnostic yield
Cost and access limitations
Selected indications
Neurologic dysphagia workup alternative diagnosis
Mediastinal process evaluation when CT contraindicated
Interpretation limitations
Reflux events not reliably captured
Dynamic physiologic condition
Better assessed by pH impedance testing
CT
Indications for CT imaging
Alternative diagnosis concern
Aortic pathology phenotype
Pulmonary embolism phenotype
Complication concern
Perforation concern
Abscess concern
Severe abdominal pain with systemic signs
Peritonitis signs
Sepsis concern
CT findings that support reflux complications
Esophageal wall thickening
Esophagitis possibility
Nonspecific finding
Hiatal hernia
Predisposition to reflux
Size correlates with symptom severity imperfectly
Pneumomediastinum
Perforation concern
Urgent surgical evaluation trigger
Decision rule and guideline integration
Avoid CT for uncomplicated typical GERD symptoms
Radiation risk without benefit
Prefer empiric therapy or endoscopy based on features
Ultrasound
Abdominal ultrasound for biliary mimic
RUQ pain phenotype
Gallstones
Gallbladder wall thickening
Murphy sign correlation
Positive sign supports cholecystitis
Negative sign does not fully exclude
Point-of-care ultrasound adjuncts
Cardiac POCUS for chest pain alternative
Pericardial effusion
Regional wall motion abnormality context
Lung POCUS for respiratory symptoms
Pneumothorax signs
Consolidation suggesting aspiration
Endoscopy
Upper endoscopy indications
Alarm features
Dysphagia
GI bleeding
Refractory symptoms despite optimized PPI
Persistent symptoms after adequate trial
Uncertain diagnosis
Barrett screening consideration in higher-risk phenotype
Multiple risk factors present
Long-standing frequent symptoms
Endoscopic findings
Erosive esophagitis
LA classification framework use
Higher grades correlate with GERD
Barrett esophagus
Columnar mucosa in distal esophagus
Biopsy required for intestinal metaplasia confirmation
Stricture
Luminal narrowing
Dilation consideration
pH monitoring and manometry
Ambulatory pH or pH impedance testing
Diagnostic uncertainty with normal endoscopy
Objective reflux confirmation
Symptom association analysis
Preoperative evaluation for anti-reflux surgery consideration
Objective reflux confirmation
Predicts surgical benefit
Esophageal manometry
Dysphagia evaluation for motility disorders
Achalasia pattern
Hypercontractile disorders
Preoperative planning
Major motility disorder exclusion
Wrap selection guidance
Disposition
ED and inpatient decision points
Admission criteria
Inability to tolerate oral intake
Dehydration requiring IV fluids
Persistent vomiting
GI bleeding
Hemodynamic changes
Significant anemia
Suspected perforation
CT or clinical evidence
Need for surgery or ICU monitoring
High-risk chest pain not ruled out
Abnormal ECG
Troponin elevation
Observation unit criteria
Chest pain low to intermediate risk requiring serial testing
Serial troponin completion
Stress testing or CT coronary angiography per protocol
Refractory symptoms requiring short-term symptom control
IV antiemetics or acid suppression
Oral challenge prior to discharge
Discharge criteria and follow-up
Safe discharge phenotype
Typical symptoms without alarm features
Stable vitals
Tolerating oral intake
Symptoms responsive to initial therapy
Relief with antacid or PPI
No concerning exam findings
Follow-up planning
Primary care or gastroenterology referral
Persistent symptoms after initial course
Recurrent symptoms needing long-term plan
Endoscopy referral triggers
Any alarm feature
Refractory symptoms despite optimized regimen
Treatment
Nonpharmacologic management
Lifestyle and behavioral therapy
Weight reduction when overweight or obese
Symptom improvement expectation
Lower intra-abdominal pressure rationale
Meal timing and portion adjustments
Avoid large meals
Avoid eating within 2 to 3 hours of bedtime
Head-of-bed elevation for nocturnal symptoms
Bed risers or wedge pillow
Avoid stacked pillows only
Trigger identification and reduction
High-fat meals
Caffeine if clearly linked
Tobacco cessation
LES tone improvement rationale
Barrett and cancer risk reduction rationale
Acid suppression and mucosal protection
Medication strategy selection
Typical symptoms without alarm features
Initial PPI trial
Duration 8 weeks
Dosing once daily before breakfast
Step-down after response
Lowest effective dose
On-demand use option for nonerosive disease
Mild intermittent symptoms
Antacids or alginate-based therapy
Rapid symptom relief role
Breakthrough symptom use
Proton pump inhibitors
Omeprazole PO 20 mg daily
If partial response, increase to 20 mg twice daily
Second dose before dinner
Reassess after 4 to 8 weeks
Maximum typical outpatient dosing 40 mg twice daily
Use for refractory or erosive disease phenotype
De-escalate when controlled
Pantoprazole PO 40 mg daily
If partial response, increase to 40 mg twice daily
Timing 30 to 60 minutes before meals
Check adherence and timing before escalating
Maximum typical outpatient dosing 40 mg twice daily
Shortest effective duration principle
Long-term risk counseling
Esomeprazole PO 20 mg daily
If partial response, increase to 20 mg twice daily
Consider CYP2C19 variability context
Avoid duplication with other PPIs
Maximum typical outpatient dosing 40 mg twice daily
Consider specialist input at high dose
Objective testing for refractory symptoms
H2 receptor antagonists
Famotidine PO 10 mg to 20 mg as needed
Breakthrough symptoms on PPI
Bedtime dose for nocturnal acid breakthrough
Tolerance with nightly use
Renal impairment dose adjustment
Lower dose with reduced eGFR
Monitor confusion risk in older adults
Famotidine PO 20 mg twice daily
Mild to moderate symptoms alternative
Less effective than PPI for erosive esophagitis
Consider step-up to PPI if persistent
Maximum typical dose 40 mg twice daily
Avoid prolonged high-dose without reassessment
Consider endoscopy if persistent symptoms
Antacids and alginates
Calcium carbonate PO 500 mg to 1000 mg as needed
Rapid relief role
Short duration effect
Avoid overuse with hypercalcemia risk
Constipation risk
Hydration advice
Alternative antacid selection
Alginate-based therapy after meals and at bedtime
Postprandial reflux barrier mechanism
Useful for regurgitation phenotype
Add-on to PPI for symptoms
Sodium load consideration
Heart failure patients caution
Hypertension patients caution
Sucralfate
Sucralfate PO 1 g four times daily
Pregnancy symptom option
Minimal systemic absorption
Constipation risk
Drug interaction spacing
Separate from other meds by 2 hours
Reduced absorption risk
Refractory symptoms and optimization
Optimization checklist before labeling refractory GERD
Adherence verification
Daily dosing
Missed doses frequency
Timing correction
30 to 60 minutes before breakfast
Before dinner for twice daily regimens
Phenotype reassessment
Functional heartburn possibility
Reflux hypersensitivity possibility
Next steps when persistent symptoms
Objective testing consideration
Endoscopy for alarm features or long-standing symptoms
pH impedance testing for uncertain diagnosis
Alternative diagnoses evaluation
Eosinophilic esophagitis
Achalasia
Adjunctive therapies by phenotype
Bedtime H2RA for nocturnal symptoms
Alginate therapy for regurgitation
Procedural and surgical options
Anti-reflux procedures
Laparoscopic fundoplication
Indications
Objective GERD with persistent symptoms
Preference to avoid long-term medication
Preoperative workup
pH testing confirmation when endoscopy nonerosive
Manometry to exclude major motility disorder
Evidence statement
Class I recommendation for surgery in selected patients with objective reflux and appropriate workup
Shared decision-making on dysphagia and gas-bloat risks
Magnetic sphincter augmentation
Indications
Objective GERD with normal motility
Regurgitation predominant phenotype
Contraindications
Severe esophagitis
Large hiatal hernia without repair plan
Endoscopic therapies
Selected patient use
Mild to moderate disease phenotype
Not for high-grade esophagitis
Counseling on durability limits
Variable long-term outcomes
Continue surveillance for complications
Special Populations
Pregnancy
Pregnancy-focused approach
Nonpharmacologic first
Smaller meals
Head-of-bed elevation
Medication escalation sequence
Antacids
Calcium carbonate preferred option
Avoid sodium bicarbonate routine use
Sucralfate
Minimal systemic absorption
Constipation counseling
H2RA
Famotidine commonly used
Use lowest effective dose
PPI for persistent symptoms
Use when benefits outweigh risks
Consider obstetric input for severe disease
Hyperemesis overlap caution
Persistent vomiting evaluation
Dehydration and electrolyte monitoring
Geriatric
Older adult considerations
Atypical presentation
Less prominent heartburn
More dysphagia or cough
PPI risk mitigation
Use lowest effective dose
Periodic deprescribing attempt
Adverse effect awareness
C difficile infection association
Fracture risk association
Polypharmacy and interactions
Antiplatelet therapy context
Mineral supplementation timing
Pediatrics
Pediatric reflux versus GERD distinction
Physiologic reflux in infants
Frequent regurgitation with normal growth
Reassurance and feeding guidance
GERD indicators
Poor weight gain
Feeding refusal
Pediatric management approach
Nonpharmacologic first-line in infants
Avoid overfeeding
Thickened feeds when appropriate
Medication use caution
Acid suppression only when clear GERD phenotype
Short trial with reassessment
Specialist referral triggers
GI bleeding
Persistent dysphagia or food impaction
Background
Epidemiology
Population burden
Common condition in adults
High prevalence in primary care and ED chest pain mimic
Frequent chronic or relapsing course
Risk factors
Obesity association
Hiatal hernia association
Complication risk
Barrett esophagus risk increases with long-standing frequent symptoms
Esophageal adenocarcinoma risk increases with Barrett presence
Pathophysiology
Core mechanisms
Lower esophageal sphincter dysfunction
Transient LES relaxations
Reduced basal LES tone
Hiatal hernia contribution
Disruption of gastroesophageal junction barrier
Increased reflux episodes when supine
Impaired esophageal clearance
Reduced peristalsis
Reduced salivary buffering
Gastric factors
Delayed gastric emptying
Increased gastric volume after large meals
Therapeutic Considerations
PPI pharmacology pearls
Best effect with pre-meal dosing
Proton pump activation with meals
Suboptimal effect with bedtime-only dosing
Time to maximal benefit
Several days for full acid suppression
Avoid premature escalation before optimization
Deprescribing principle
Step-down after symptom control
On-demand use for nonerosive disease when appropriate
Long-term acid suppression risks
Association signals
Enteric infection risk
Hypomagnesemia risk
Risk reduction strategies
Lowest effective dose
Periodic reassessment of ongoing indication
Extraesophageal symptom caution
Chronic cough and laryngeal symptoms have multifactorial causes
Avoid assuming GERD without supportive features
Consider objective testing before prolonged high-dose PPI
Patient Discharge Instructions
copy discharge instructions
Diagnosis and expectations
Symptoms consistent with acid reflux
Often improves with lifestyle changes and acid-lowering medicine
May take several days for best effect with daily PPI
Medication plan
Take PPI 30 to 60 minutes before breakfast
Do not stop suddenly if symptoms severe without plan
Home care
Meal and sleep changes
Avoid large meals
Avoid eating within 2 to 3 hours of bedtime
Bed positioning
Raise head of bed
Sleep on wedge if needed
Trigger tracking
Note foods that worsen symptoms
Reduce those triggers if consistent
Return to ED now if any occur
Chest pain with exertion
Pressure or squeezing quality
Sweating or shortness of breath
Trouble swallowing
Food stuck
Drooling or inability to swallow liquids
Vomiting blood or black stools
Red or coffee-ground vomit
Black tarry stool
Severe or worsening belly pain
Pain with fever
Rigid abdomen
Unintentional weight loss
Ongoing loss over weeks
Progressive weakness
Follow-up
Primary care in 1 to 2 weeks if not improving
Medication adjustment
Referral discussion
Gastroenterology referral triggers
Any trouble swallowing
Symptoms not improving after an adequate trial
References
Clinical guidelines and society statements
Guideline sources
American College of Gastroenterology guideline for GERD management
Empiric PPI trial for typical symptoms without alarm features
Endoscopy for alarm features and selected refractory cases
American Gastroenterological Association clinical practice updates on PPI use
Use lowest effective dose
Deprescribing when no ongoing indication
NICE guidance for dyspepsia and GERD
Stepwise therapy and review
Referral for alarm features
ACEP clinical policies relevant to chest pain overlap
Level A or Level B recommendations for ECG and troponin in suspected ACS pathways
Discharge criteria for low-risk chest pain per institutional protocol
Evidence-based sources and decision support
Foundational evidence
PPI superiority over H2RA for healing erosive esophagitis
Higher healing rates in trials and meta-analyses
Symptom control benefit in frequent heartburn
Ambulatory reflux monitoring utility
Objective confirmation for refractory symptoms
Symptom association analysis value
Preoperative testing standards for anti-reflux surgery
pH monitoring when diagnosis uncertain
Manometry to exclude major motility disorder
SymptomDx is an educational tool for medical professionals. It does not replace clinical judgment. Verify all clinical data and drug dosages with authoritative sources.